Mefloquine has been one of the more valuable antimalarial drugs, but has never reached its full clinical potential due to concerns about its neurologic side effects, its greater expense relative to other antimalarials, and the emergence of resistance. The commercial development of mefloquine superseded that of another quinolinyl methanol, WR030090, which was used as an experimental antimalarial by the U.S. Army in the 1970s. We evaluated a series of related 2-phenyl substituted alkylaminoquinolinyl-methanols (AAQMs) for their potential as mefloquine replacement drugs, based on a series of appropriate in vitro and in vivo efficacy and toxicology screens and theoretical cost of goods. Generally, the AAQMs were less neurotoxic, exhibited greater antimalarial potency and are potentially cheaper than mefloquine, but showed poorer metabolic stability and pharmacokinetics and the potential for phototoxicity. These differences in physiochemical and biological properties are attributable to the 'opening' of the piperidine ring of the 4-position side chain. Modification of the most promising compound, WR069878, by substitution of an appropriate N functionality at the 4-position, optimization of quinoline ring substituents at the 6 and 7-positions, and deconjugation of quinoline and phenyl ring systems, is anticipated to yield a valuable new antimalarial drug.
INTRODUCTION
In the late 1960s to early 1970s, Plasmodium falciparum malaria in South East Asia had begun to develop resistance to all of the available antimalarial drugs (6) . Cure rates were 11-20% and 26-50% for chloroquine and quinine, respectively, and had declined to only 90% for the triple combination of quinine/pyrimethamine/dapsone (6) . All these regimens were associated with adverse side effects (6) . As a consequence, the U.S. Army began routinely employing two experimental antimalarial drugs, WR030090 and WR033063, for the treatment of recrudescent malaria infections at the Walter Reed Army Medical Center (6) . Subsequent field trials demonstrated that WR030090, a quinolinyl methanol, exhibited cure rates of at least 88% and was better tolerated than quinine (6, 21) .
Shortly thereafter, mefloquine was discovered and was developed commercially by Hoffman La Roche and the U.S. Army. Mefloquine exhibited a long half-life in humans, and this desirable property facilitated its administration as a single dose for malaria treatment and as a once weekly dosing for prophylaxis (50) . In contrast, WR030090 was only partially effective as a prophylactic agent, required a similar dosing regimen as quinine to effect cures, and was subsequently abandoned (6, 9, 21, 30) . However, it is important to recognize that this occurred because of unfavorable pharmacokinetic characteristics, not as a consequence of unacceptable toxicity.
Mefloquine combined with artesunate remains one of the most effective combination agents for treatment of malaria (41) . Mefloquine is also the only once-weekly drug
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from approved for malaria chemoprophylaxis in the United States, that, barring the Thai border regions, is effective in almost all areas of the world. (7) . However, mefloquine is relatively expensive compared to other antimalarials (8) , which limits its accessibility to developing countries. Also, mefloquine use is associated with debilitating neurological effects in a small proportion of patients, and milder, but nevertheless concerning effects are also frequently observed (31, 40, 43, 47) . These negative characteristics have limited the scope of the possible clinical utility of the drug.
In the present study, we report the antimalarial activity and pharmacological properties of a number of 2' substituted alkyl amino quinoline methanols related to WR030090. Our goals were to (i) develop an understanding of structure activity relationships that might allow the synthesis of improved quinolinyl methanols and (ii) determine whether compounds related to WR030090 might prove to be more efficacious antimalarials. 
on
MATERIALS AND METHODS
In vitro antimalarial activity of AAQMs. The in vitro activities of AAQMs against P. falciparum strains W2, D6, TM91C235 and TM90C2A were evaluated using the method of Desjardins et al. 1979 (12) , as modified by Milhous et al. 1985 (32) and described in one of our earlier papers (16) . W2 is chloroquine resistant and mefloquine sensitive, D6 is chloroquine sensitive but naturally less susceptible to mefloquine, TM91C235 is resistant to mefloquine, chloroquine and pyrimethamine as is TM90C2A, however this latter parasite is a two pfmdr1 copy strain. We routinely run mefloquine in this screen as a control to ensure assay validity. Mefloquine has a mean IC50 +/-SD against P. falciparum TM91C235 of 15.7 +/-2.7 ng/ml (last 15 assays).
Antimalarial activity of AAQMs in mice and monkeys. The P. berghei-mouse efficacy data were obtained from the WRAIR chemical information system (subcutaneous testing) or from recent tests conducted at AFRIMS, Thailand or at the University of Miami using a modified version of the Thompson test. Basically, groups of five mice were inoculated through i.p. injection on day 0 (usually with 1 x 10 6 P. berghei-parasitized erythrocytes).
Drugs were administered either subcutaneously or orally for three days (usually on days 3-5) at doses of 1.25 -160 mg/kg in two to four fold increments. Cure was defined as survival until day 60 (subcutaneous dosing) or day 31 post-treatment (oral dosing). Nontreated control mice usually die on day 6-10 post-infection. The minimum effective dose was the lowest dose level that cured at least one of five mice. The Aotus studies were performed as previously described (35, 36) . Briefly, groups of two Aotus lemurinus In some instances, a high dose of the test drug was used to retreat monkeys instead of the mefloquine rescue. Monkeys are considered cured if they are parasite free 90 days post treatment. For the P. falciparum studies, the dose rate selected was 10 mg/kg/day x 7, since earlier studies suggested that WR030090, a compound that later proceeded to clinical studies, cleared but did not cure infections at this dose (WRAIR archival data).
A C C E P T E D
Cure at this dose for related analogs would therefore be a good indicator of their superiority over a compound that had already proceeded into clinical development. dehydrogenase to a final concentration of 1 unit/ml. The reactions were maintained at 37°C until they were terminated by the addition of an equal volume of 100% ice cold acetonitrile at 0, 10, 30, 60, and 120 minutes. Samples were centrifuged to pellet the proteins and the supernatant was analyzed by LC-MS/MS in duplicate using fast LC gradient or isocratic methods. Parent drug was quantified with external calibration, using plots of parent drug response v. amount. Chromatograms were analyzed using the mass spectrometry software Xcalibur™ QuanBrowser (for ThermoFinnigan® instruments) or
MassLynx™ (for Waters® instruments). Concentrations of parent drug remaining at each time point were calculated using the unknown peak areas and corresponding calibration curves. In order to calculate the half-life, a first-order rate of decay was assumed. A plot of the natural log (LN) of the drug concentration versus time was generated, where the slope of that line was -k. Half-life was calculated as 0.693/k. The positive control tested with each of these assays was nifedipine, which exhibited a mean half-life +/-SD of 31.7
+/-5.3 min with human liver microsomes and 27.6 +/-2.6 min with mouse liver microsomes (based on 5 assays). Mefloquine, which has been run >5 times in this assay, consistently exhibits a half-life of > 120 min in the presence of both human and mouse
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For metabolite identification, samples were prepared as described above with human liver microsomes. Additional samples were prepared with each drug using mouse, rat, and rhesus monkey liver microsomes. Samples were separated using an LC gradient method and analyzed by full scan LC-MS and LC-MS/MS. Parent compound and putative metabolites were all fragmented, and these MS/MS experiments were used in combination with the no-NADPH control experiments to confirm the assignment of peaks as metabolites. These MS/MS data were also used to do preliminary structural elucidation. Although dealkylated metabolites could be straightforwardly identified, the regioselectivity of other modifications, specifically the position(s) of hydroxylation, could not be definitively ascertained. The relative percentage of formation of each metabolite was determined in a semi-quantitative manner since standards of each metabolite were not available. Peak areas of each metabolite and the internal standard were determined, and their ratios were calculated as metabolite area/internal standard area. The percent formation of each metabolite was determined as the area ratio divided by the sum of all the metabolite area ratios.
Cytochrome P450 inhibition assays. Two assays were used to evaluate the drug-drug interaction potential of the compounds. An LC-MS-based assay was first used as a prescreen of all the compounds against each isozyme, then confirmation of significant inhibition was performed using the standard fluorometric assay. The LC-MS assay was Quantification of the production of specific metabolites from each CYP substrate was performed using LC-MS. Known inhibitors for each isoenzyme (quinidine, sulfaphenazole, tranylcipromine and ketoconazole) were used as positive controls for the inhibition of specific enzymatic activity. The inhibition obtained from the test drug was expressed as a percentage of the controls without inhibitors. In general, inhibition of enzymatic activity seen at test drug concentrations of >50 µM were not considered to be significant enough for further evaluation. Values between 10 and 50 µM were considered to be moderate inhibition and lower than 10 µM were significant. (N,N-diethylamino)ethyl]-7-hydroxy-4-methylcoumarin hydrochloride (AHMC), the fluorescent metabolite, was quantified using a fluorescence plate reader. IC 50 values were then calculated as described using the two concentrations that bracket 50% inhibition.
IC 50 values for the control, quinidine, were in each case found to be within the accepted range of 0.001 -0.05 µM as specified by the manufacturer.
Neurocytotoxicity, neuroprotection assays and confocal microscopy. The neurocytotoxicity assay of AAQMs was conducted as previously described (16) . This assay utilizes primary rat forebrain neurons and is a multi-endpoint screen. In this system a large component of the neurotoxicity of mefloquine can be attributed to the disruption of calcium homeostasis via discharge of the endoplasmic reticulum calcium store and activation of ill-defined plasma membrane calcium channels (14, 15) . Mefloquine may also induce other, uncharacterized effects in these cells. Compounds were screened at 10, 100 and 1000 µM in triplicate, and the reduction in viability observed was determined Neuroprotection experiments with 6,7-dinitroquinoxaline-2,3-dione (DNQX) and magnesium were performed as described previously (14) . Basically, neurons were exposed to DNQX (100 µM) or magnesium (12 mM) for 5 min, followed by mefloquine The effects of mefloquine and WR069878 on neuronal calcium homeostasis were assessed utilizing confocal microscopy as described elsewhere (16 Phototoxicity pharmacophore and 3T3 neutral red uptake phototoxicity test. We attempted to develop a pharmacophore for phototoxicity to be used as an in silico screening tool. An earlier study reported the minimum phototoxic concentration for a range of different quinolinyl methanols in a yeast assay system (22) . These data were used to generate a three-dimensional pharmacophore model using the HypoGen algorithm of the CATALYST® (Accelrys software Inc.) methodology as previously described (2, 16). The structures of clinically used quinoline methanols were mapped onto the pharmacophores and estimated values for minimum phototoxic concentration were generated.
The 3T3 neutral red uptake (NRU) phototoxicity test, conducted by MB Research Laboratories (Spinnerstown, PA), was used to identify quinoline methanols that have the potential to exert in vivo phototoxicity after systemic application. Briefly, the central 60 wells of two 96-well plates per test compound were seeded with Balb/c 3T3 mouse fibroblast cells and maintained in culture for 24 hrs. These plates were then pre-incubated with a range of eight different concentrations of test compound (six wells per concentration) for one hour. Next, one plate was treated with a UVA dose of 5 J/cm 2 by irradiating for 50 min at 1.7 mW/cm 2 , whereas the other plate remained non-treated and in the dark. Next, the treatment medium was replaced with culture medium and cell viability was determined after 24 hrs by measuring neutral red uptake for 3 hrs. Finally, should afford the quinoline core (37) . Conversion of the quinoline acid to the acid chloride could be accomplished with either thionyl chloride or oxalyl chloride (25) .
Conversion of the acid halide to the α-halo ketone could be accomplished through the diazoketone (1, 19, 25, 26) . Treatment of the α-halo ketone with sodium borohydride should afford the epoxide (3, 29) . Lastly, the epoxide could be opened with dibutyl amine to give an enantiomeric secondary alcohol (4, 18, 33) . Relative metabolic stability of AAQMs. Many of the AAQMs tested were less metabolically stable than mefloquine in vitro (Table 1) . Singly alkylated analogs (secondary amines) showed metabolic stability similar to that associated with mefloquine (WR176399 and WR007524, Table 1 ). In contrast, many of the dialkylated analogs were

on November 3, 2017 by guest http://aac.asm.org/ Downloaded from less metabolically stable (Table 1 ). The N,N-dialkyl analogs were metabolized in all species primarily (> 90%) by N-dealkylation (26) , yielding the corresponding secondary amine metabolite, as in WR069878 (Figure 2 ). Hydroxylation was a minor but secondary route of metabolic transformation. Singly alkylated analogs were metabolized to a much lesser extent via hydroxylation (WR176399), and/or N-dealkylation (WR041294), or not at all (WR007524). Metabolism was similar across all the species tested (rat, human, mouse, and rhesus). In cytochrome P450 inhibition assays, many of the analogs were more potent inhibitors of cytochrome CYP2D6 relative to inhibition caused by mefloquine (IC 50 of 18.6 µM), and one compound (WR069878) showed inhibitory activity equivalent to mefloquine (Table 1 ).
In vivo antimalarial activity of AAQMs. In terms of in vivo activity, almost all of the AAQMs exhibited some curative effects in the P. berghei-mouse model when administered subcutaneously (Table 1) . With the exception of WR030090 and WR211679 (which had higher IC 50 values), all AAQMs with an IC 50 < 10 ng/mL were screened orally in the mouse. With the exception of WR177973, all were substantially more effective by the oral route, with minimum curative doses ranging from < 1.25-10 mg/kg/day for 3 days for most analogs (Table 1) , although one must consider the fact that for the oral dosing experiment, survival was assessed at day 31 instead of day 60. The least neurotoxic of these were then tested for efficacy against P. falciparum in Aotus.
Cures were observed with WR069878 and WR035058 (Table 1 ). WR074086 and WR176399 cleared parasitemias, but recrudescence was subsequently observed (Table   1) . Clinical failure was associated with high in vitro IC 90 (≥20 ng/ml) against P.
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None of the observed changes in complete blood counts, serum chemistry, or body weight were attributable to toxicity. Adverse changes in hematocrit, hemoglobin, platelet, white blood cell and reticulocyte counts were observed with malaria infection, but resolved upon treatment with either mefloquine (rescue) or the AAQMs.
AAQM plasma concentrations in monkeys.
Overall, plasma concentrations of the six AAQMs in Aotus monkeys were relatively low (mean peak concentrations of 28-413 ng/ml with a 10 mg/kg/day oral dose x 7, Table 3 ) compared to what one would usually observe after a single mefloquine treatment dose (peak concentrations of 800 -8000 ng/ml, (49)). Lower than expected plasma concentrations for AAQMs may be due to a combination of several contributing factors. Firstly, some of the AAQMs tested were less metabolically stable than mefloquine, which could potentially result in lower overall plasma concentrations of the parent compound (Table 1) . Secondly, most of the AAQMs were several orders of magnitude less soluble than mefloquine (Table 1) . It is likely that the higher solubility of mefloquine is attributable to the more polar secondary amine of the piperidine ring, whereas most of the other AAQMs contained more aliphatic tertiary amines. Finally, the predicted Log P values for most of the AAQMs were substantially higher than mefloquine, and furthermore, substantially greater than that normally observed for commercially available drugs (Table 1 , (24) . Indeed, poor solubility and permeability are the two leading causes for poor drug absorption (24) . Figure 3 ). This effect does not result from a difference in solubility, since both drugs dissolved without evidence of precipitation across the concentration range tested. The mechanism of neurotoxicity of mefloquine also appears to be different, since WR069878 did not disrupt calcium homeostasis to the same extent as mefloquine ( Figure 3 ). In addition, the neurotoxicity of WR069878 was not Table 6 ). WR007930 is historically associated with phototoxicity in Phase I clinical trials, whereas, WR030090 progressed to Phase II clinical trials without phototoxicity being deemed a significant concern (30, 42) .
A C C E P T E D
Mefloquine mapped all the features of the pharmacophore, with the exception of an aromatic hydrophobic functionality associated with the phenyl ring at the 2-position, with an estimated minimum phototoxic concentration of 5600 mg/ml (Table 6 ). In addition to the pharmacophore assessment, these quinoline methanols were also tested in the 3T3 
on November 3, 2017 by guest http://aac.asm.org/ Downloaded from respectively), whereas mefloquine scored a PIF of 1.76, and therefore, as expected, is not considered phototoxic (Table 6 ). Thus, the pharmacophore, and the 3T3 NRU test, and other models outlined in Table 6 are all able to predict the absence of phototoxicity, but cannot grade the degree of potential phototoxicity. WR069878 exhibited a PIF of 107.7
in the 3T3 assay and a minimum phototoxic concentration of 1200 mg/ml in the pharmacophore model, suggesting the potential for phototoxicity.
Synthesis scheme for WR069878 and WR030090. We developed a synthetic scheme for WR069878 and WR030090 modeled after one published for mefloquine ( Figure 5 ).
Based on a bench-scale synthesis, the two dialkylaminoquinolinyl methanols were much less costly to produce than mefloquine ( Table 5 ). The cost of a treatment course of each drug can be extrapolated based on the known or estimated effective dose. Using this scheme, the cost of treatment for WR069878 or a similar drug would likely be substantially lower than mefloquine. This analysis has two caveats. First, difference in cost of production between bench and industrial scale was assumed to be equivalent to mefloquine. Second, the synthesis of WR069878 is complicated by the lack of a commercially available source of starting material ( Figure 5 ). Furthermore, "fromscratch" synthesis of this material would result in the synthesis of two isomers, the resolution of which could potentially be complicated for an industrial scale synthesis. 
DISCUSSION
We have identified WR069878 as the most promising molecule from a group of structurally similar compounds. WR069878 was shown to be orally active without toxicity against P. berghei in mice and chloroquine-resistant P. falciparum and P. vivax in monkeys. The compound is also an order of magnitude more potent than mefloquine against mefloquine-resistant strains of P. falciparum in vitro. We have also shown that WR069878 is intrinsically less neurotoxic than mefloquine, and appears to exhibit a different mechanism of neurotoxicity in vitro. Furthermore, the cost of treatment with WR069878 (and a related quinoline, WR030090) has been estimated to be much lower than mefloquine. These favorable characteristics argue for further development of the compound. However, the potential phototoxicity of the molecule, its relative lack of metabolic stability, and the lack of commercially available starting materials suggest a more cautious approach. In the discussion that follows, we outline the structural basis for each of these characteristics and suggest modification to the molecular scaffold that is expected to yield a new antimalarial agent. Finally we discuss the likely clinical use of such a drug given the concern about potential cross-resistance to mefloquine.
Several lines of evidence suggest that the neurotoxicity of mefloquine, as assessed in the present study, appears to be associated with the piperidine ring. We showed in an earlier study (16) that 4-quinolinecarbinolamines, which possess the piperidine functionality at the 4-position, exhibit calcium-dependent neurotoxicity at a similar level of potency to mefloquine. In the present study, we show that 'opening' of the piperidine ring correlates
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from with lower neurotoxic potency. Furthermore, the reduced neurotoxicity of both WR069878 (this study) and chloroquine (14, 16) , is associated with a failure to disrupt calcium homeostasis in the same manner as mefloquine. It is likely that this screen has in vivo relevance, since mefloquine induces neuronal degeneration consistent with a necrotic effect in rats (13) . Of course, it remains to be determined whether this physiological effect caused by mefloquine is solely responsible for its neuropathological effects in vivo. Indeed, mefloquine accumulates in the central nervous system and has been shown to interact with numerous cellular targets within a concentration range that one could reasonably consider pharmacological (10, 15, 20, 23, 28, 39, 51) . Furthermore, it is interesting to note that others have reported that the substitution of the piperidine ring with a pyridine ring also reduces the potency of mefloquine against at least one of these other potential neurological targets (28) .
Replacement of the piperidine ring with 2 non-cyclic alkyl side chains to form a tertiary amine renders these compounds more metabolically labile and susceptible to Ndealkylation. Moreover, the nitrogen side chain appears to be less vulnerable to Ndealkylation if the chains are shortened or if only a single chain is present (a secondary amine). This modification, interestingly, also appears to make the compounds more biologically active. Therefore, it seems possible to modify the SAR of the N-alkyl side chain, such that the ideal balance between metabolic stability, biological activity, and cost of goods is obtained. One approach to achieve this goal might be to include an Nfunctionality in a non-piperidine ring system, either in the form of a pyridine ring (shown by Maertens et al. 2000 to be less toxic in vitro to anion channels), a quinuclidine ring in which the piperidine ring of mefloquine was replaced with a quinuclidine ring (46) , although the veracity of this claim is difficult to judge given that mefloquine was not included as a positive control in these neurological studies.
Phototoxicity is potentially a problem with this class of drugs (42) . However, for various reasons there are no useful data available to determine whether WR069878 or analogs would be likely to induce clinically important phototoxicity. First, the one study that reported in vivo phototoxicity (in mice) with WR069878 did not specify the route of administration beyond the fact that the compound was 'injected' (22) . Second, quinolinyl methanols are not uniformly phototoxic in the clinical setting (Table 6 ). Third, amongst the various test systems for phototoxicity, there are no comparable data for all the quinolinyl methanols (Table 6 ). We therefore attempted to resolve this issue by developing a phototoxicity pharmacophore and utilizing the 3T3 NRU assay to rank the three compounds with which there is clinical experience. If successful, this approach may have had utility as an in silico screen for phototoxicity.
Pharmacophore mapping correctly identified mefloquine as a non phototoxic drug, however WR030090 and WR007930 were indistinguishable (Table 6 ). This mapping also indicated that the feature which did not map to mefloquine was the aromatic hydrophobic functionality associated with the phenyl group at the 2-position. The 3T3 assay was also able to clearly distinguish the lack of phototoxicity of mefloquine but did not rank
on November 3, 2017 by guest http://aac.asm.org/ Downloaded from WR007930 and WR030090 correctly. Thus, the pharmacophore, 3T3 assay and other screens listed in Table 6 appear to be capable of ruling out phototoxicity, but not ranking related molecules in terms of the degree to which they could induce phototoxicity. The results of both of these screens suggest the potential for phototoxicity with WR069878.
However, it may be possible to engineer out the phototoxicity of WR069878, since it is thought that the phototoxicity of quinoline methanols is due to extensive π-conjugation of the quinoline and phenyl ring systems (44) . With mefloquine, this was avoided by addition of a trifluromethyl group at the 2-position. However, addition of a phenyl ring system improves intrinsic antimalarial activity. Future studies should be directed towards investigating the SAR balance between phototoxicity and antimalarial activity at the 2-position. The phototoxicity pharmacophore could then be used as an in silico screening tool to rule out phototoxicity prior to synthesis of new analogs.
Cost of goods is an important factor to consider when evaluating new antimalarial drugs,
given that the disease is prevalent in developing countries. We have estimated that WR069878 and related compounds are likely to be less expensive to produce than mefloquine based on comparing the respective bench-scale syntheses for these compounds. Using this method, we determined that the starting materials needed for WR069878 are generally less expensive and also feature more reliable and higher yielding chemical steps. Furthermore, we anticipate that commercial process chemistry using more cost-effective bulk reagents will further improve the cost-basis of the AAQMs versus mefloquine.
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The hypothetical synthesis of WR069878 and related compounds, whilst intrinsically cheaper than mefloquine at a bench-scale, is likely to be complicated by the lack of a commercially available starting material needed for large scale synthesis. This is because the synthesis of the appropriate starting material as shown would involve separation of isomers on a large scale ( Figure 5 ). One approach to resolving this issue would be the strategic placement of blocking groups that could be easily removed on a large scale. For example, installing a methoxy functional group that would block cyclization at the undesired position and could be removed, for example with boron tribromide (BBr 3 ), should yield only the desired isomer. Alternatively, this issue might be avoided by introduction of different ring substituents at the 6, 7 and 8-positions. The present study did not, however, attempt to address the effect that such substitutions may have on intrinsic antimalarial activity, neurotoxicity, or metabolic stability.
Clinical resistance to mefloquine is mediated for the most part by amplified copy number of the gene pfmdr1 (41) . Pfmdr1 encodes PgH-1, a malaria drug efflux protein homologous to mammalian P-glycoprotin (PgP). It has been suggested that this protein is linked mechanistically to mefloquine resistance, since it acts to detoxify the malaria parasite by extrusion of the drug into the food vacuole (45) . However, clinical resistance to mefloquine may also occur in the absence of pfmdr1 amplification in some cases (41), and some parasites of West African origin exhibit a naturally lower susceptibility to mefloquine. The P. falciparum strains TM90C2A, TM91C235 and D6 used here are representative of these scenarios. In an earlier study we observed that the susceptibility of different Plasmodium strains to a series of 4-quinolinecarbinolamines tracks with that of Notes a. Primary treatment refers to the initial treatment given when parasitemia reached 5000 parasites/µL. Re-treatment refers to administration of an additional course of treatment in the event of recrudescence after, or failure of, the primary treatment. b. These strains/species are chloroquine-resistant. c. Where the outcome of treatment was clearance, the number in brackets indicates the number of days before parasites recrudesced. Failure Notes * Denotes position on quinoline ring at which substitution, as in Figure 1 . Groups 2a-c denote either substitution at the 2-position or modifications to the phenyl ring attached to the quinoline ring at the 2 position. Groups 4a-c denote modifications to the N side chain at the 4 position. a Trifluromethyl group is attached at 2-position of the quinoline ring. b t-Butyl group is attached to the 2-position of the quinoline ring c Piperdine ring as in Figure 1 . d N-oxide. e N-methyl. f Calculated using ACD/LogD Sol Suite. g Minimum daily dose that cured at least one of five P. berghei-challenged mice. Drugs were given s.c. for three days. h Minimum daily dose that cured at least one of five P. berghei-challenged mice. Drugs were given orally for three days. Compounds were tested at University of Miami unless otherwise indicated. Greater/less than symbols indicate that the MED was outside the dose range tested as indicated. i These compounds were tested at AFRIMS, Thailand. j Clinical outcome in groups of two P. falciparum-challenged Aotus. Cure means that both monkeys were parasite free 90 days after treatment. Failure means that monkeys were rescued with mefloquine. R means that infections were cleared, and the number indicates the average day of recrudescence for both monkeys. NT = Not tested due to insolubility or insufficient compound. 
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